Oteseconazole (VIVOJA) for prevention of recurrent vulvovaginal candidiasis

Trends Pharmacol Sci. 2023 Jan;44(1):64-65. doi: 10.1016/j.tips.2022.10.004. Epub 2022 Nov 14.
No abstract available

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Candidiasis, Vulvovaginal* / drug therapy
  • Candidiasis, Vulvovaginal* / prevention & control
  • Female
  • Humans

Associated data

  • ClinicalTrials.gov/NCT01891331
  • ClinicalTrials.gov/NCT02267382
  • ClinicalTrials.gov/NCT03562156
  • ClinicalTrials.gov/NCT02267382
  • ClinicalTrials.gov/NCT03561701
  • ClinicalTrials.gov/NCT03840616